Mechanistic insights into the anticancer potential of ruthenium(II) paracymene complexes of phenolic acids
- 16 February 2026
- journal article
- research article
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 399 (8) , 11241-11267
Abstract
Organometallics, specifically ruthenium (Ru)-based complexes, have emerged as promising anticancer agents, offering controlled reactivity, electronic versatility, and tunable lipophilicity. The present work focuses on elucidating detailed anticancer cellular mechanisms of Ru(II)-gallate and Ru(II)-vanillate against MCF-7 breast and HepG2 liver cancer cells. Cell death pattern was assessed by flow cytometry, reactive oxygen species (ROS) level and mitochondrial membrane potential were measured by fluorescence assay, and the expression of key apoptosis-related proteins and genes were quantified by Western blot and quantitative reverse transcription polymerase chain reaction, respectively. Acute toxicity study was conducted in female Swiss albino mice. Mechanistic assays confirmed that both complexes substantially disrupted intracellular redox homeostasis, as evidenced by characteristic alterations in reduced glutathione/oxidized glutathione ratio indicative of reductive stress, leading to mitochondrial membrane depolarization, induced apoptotic cell death, suppressed anti-apoptotic protein B-cell lymphoma-2 (Bcl-2), pro-caspase-3 levels (in HepG2 cells only), promoted mitochondrial cytochrome c release, elicited a concomitant rise in caspase-9, and upregulated Bcl-2-associated X-protein. The protein expression profile was further supplemented by analysis of important genes associated with apoptosis, such as BAX, BCL2, CASP3, and CASP9, performed using quantitative reverse transcription polymerase chain reaction. Acute oral toxicity study at a limit dose of 2000 mg/kg did not reveal adverse hematological, biochemical, or histopathological alterations in mice, indicating a non-toxic outcome under the tested conditions. This study revealed that Ru(II)-gallate and Ru(II)-vanillate induce mitochondria-mediated apoptosis driven by reductive stress, and exhibited strong in vivo tolerability, underscoring their potential as attractive contenders for cancer treatment pending further evaluation. Graphical AbstractKeywords
This publication has 67 references indexed in Scilit:
- Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategiesMedical Oncology, 2025
- Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapyDiscover Oncology, 2025
- Cellular Mechanistic Considerations on Cytotoxic Mode of Action of Phosphino Ru(II) and Ir(III) ComplexesEuropean Journal of Inorganic Chemistry, 2023
- 14-Deoxy-11,12-didehydroandrographolide inhibits apoptosis in influenza A(H5N1) virus-infected human lung epithelial cells via the caspase-9-dependent intrinsic apoptotic pathway which contributes to its antiviral activityAntiviral Research, 2020
- Cancer Initiation, Promotion, and Progression and the Acquisition of Key Behavioral Traits2020
- Reactive oxygen species (ROS) are a key determinant of cancer's metabolic phenotypeInternational Journal of Cancer, 2017
- Transferrin Receptor-Mediated Endocytosis: A Useful Target for Cancer TherapyThe Journal of Membrane Biology, 2014
- Western Blot Analysis2012
- Calcium, leukocyte cell death and the use of annexin V: fatal encountersApoptosis, 2007
- A novel assay for apoptosis Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin VJournal of Immunological Methods, 1995